Interferencing CD47/SIRPα axis using anti-CD47 antibodies has been effective in inhibiting the growth of certain solid tumors including melanoma, lung cancer and leiomyosarcoma (Figure 1) [78,79,80,81]. Here, CD47 is linked to melanoma.